Other languages Scilex Holding Company

Equities

SCLX

US80880W1062

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
0.87 ^USD	+6.32%		+4.79%	-57.35%

May. 14	Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute	MT
May. 14	Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute	May. 14
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute	May. 14
Scilex Issues Preliminary Q1 Sales Results for ZTlido	Apr. 16
Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label	Mar. 20
Scilex Settles Patent Dispute With Takeda Pharmaceutical Over Gloperba	Mar. 20
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba®? Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment Is Needed	Mar. 20
Scilex Holding Company Provides Responses to Product Composition Questions Related to Its ELYXYB® Patent in Canada	Mar. 18
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	Mar. 15
Scilex Holding Company Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12
Top Midday Decliners	Mar. 01
Investors Await Key Economic Data, Markets Remain Flat Ahead of Opening Bell	Mar. 01
US Futures Remain Flat as Investors Await Raft of Economic Data	Mar. 01
Scilex Holding Signs Underwriting Agreement for $10 Million Bought Deal Offering	Mar. 01
Scilex Files $500 Million Mixed-Securities Shelf	Jan. 09
Scilex Holding Company Provides Sales Guidance for the Fiscal Year Ended December 31, 2023	Jan. 02
Scilex Files New Drug Submission for Migraine Treatment Approval in Canada	Dec. 26
Scilex Holding Company Announces Filing of New Drug Submission to Health Canada's Pharmaceutical Drugs Director, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada	Dec. 26
Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal A High Degree of Interest in Gloperba as Liquid Colchicine Formulation Designed for Precision Dosing	Dec. 19
Scilex Says US Pharmacy Chain to Stock Elyxyb	Dec. 15
Scilex Holding Company Announces Major Pharmacy Initiative with the National Leading Pharmacy Chain to Stock ELYXYB® in Most of Their Stores Throughout the U.S	Dec. 15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Scilex Holding Company

Equities

SCLX

US80880W1062

Other languages

Filters